Table 2.
Demographics of Subjects with CRSwNP or AERD Evaluated in the Comparison of Inflammatory Mediator Profiles in Nasal Polyp Tissue
| CRSwNP Polyp | AERD Polyp | P Value | |
|---|---|---|---|
| Luminex protein assay, n | 15 | 15 | |
| Male sex, n (%) | 13 (87%) | 6 (40%) | 0.02 |
| White, n (%) | 13 (87%) | 8 (53%) | 0.11 |
| Mean ± SEM age, yr | 39 ± 3 | 43 ± 3 | 0.41 |
| Atopic, n (%) | 10 (67%) | 14 (93%) | 0.17 |
| Asthmatic, n (%) | 6 (40%) | 15 (100%) | <0.001 |
| Oral steroid use, n (%) | 5 (33%) | 10 (67%) | 0.14 |
| Intranasal steroid use, n (%) | 7 (47%) | 13 (87%) | 0.05 |
| Leukotriene antagonist use, n (%) | 2 (13%) | 7 (47%) | 0.11 |
| Preoperative antibiotic, use n (%) | 1 (7%) | 3 (20%) | 0.60 |
| Average ± SEM number of surgeries | 1.1 ± 0.1 | 3.3 ± 0.5 | <0.001 |
| RT-PCR for tPA, n | 20 | 19 | |
| Male sex, n (%) | 16 (80%) | 8 (42%) | 0.02 |
| White, n (%) | 14 (70%) | 14 (74%) | 1.00 |
| Mean ± SEM age, yr | 48 ± 3 | 44 ± 2 | 0.51 |
| Atopic, n (%) | 9 (45%) | 16 (84%) | 0.02 |
| Asthmatic, n (%) | 7 (35%) | 19 (100%) | <0.001 |
| Oral steroid use, n (%) | 4 (20%) | 14 (74%) | <0.01 |
| Intranasal steroid use, n (%) | 11 (55%) | 13 (68%) | 0.51 |
| Leukotriene antagonist use, n (%) | 2 (10%) | 9 (47%) | 0.01 |
| Preoperative antibiotic use, n (%) | 3 (15%) | 2 (11%) | 1.00 |
| Average ± SEM number of surgeries | 1.3 ± 0.1 | 2.5 ± 0.4 | <0.01 |
Definition of abbreviations: AERD = aspirin-exacerbated respiratory disease; CRSwNP = chronic sinusitis with nasal polyps; RT-PCR = real-time polymerase chain reaction; tPA = tissue plasminogen activator.